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http://dx.doi.org/10.1016/j.jmii.2012Background: Reduced bone mineral density (BMD) is an emerging threat to the successful long-
term management of human immunodeficiency virus (HIV) infection among patients with
access to combination antiretroviral therapy (cART). Data on the prevalence and associated
factors of reduced BMD in Asian populations remain scarce.
Methods: From March 2002 to April 2006, a cross-sectional survey was conducted among HIV-
infected patients aged  20 years at the National Taiwan University Hospital. BMD of the
lumbar spine was measured with the use of dual-energy X-ray absorptiometry. Osteopenia
was defined as a BMD T-score between 1.0 and 2.5, and osteoporosis was defined as
a BMD T-score  2.5. Linear and ordinal logistic regression analyses were performed.
Results: Among 320 patients with a median age of 37.3 years, body mass index (BMI) of
21.4 kg/m2 and 94.4% on cART, osteopenia and osteoporosis were diagnosed in 35.6% and
3.8%, respectively. On multivariate linear analysis, factors associated with reduced BMD were
increasing age (pZ 0.006), longer duration on antiretroviral therapy (pZ 0.007), and
a decreasing BMI (pZ 0.002). Using ordinal logistic regression, being underweight with a body
mass index (BMI)< 18.5 kg/m2 was independently associated with reduced BMD (proportional
odds ratio, 4.12; 95% confidence interval, 1.93e8.82).of Medical Imaging and Radiology, National Taiwan University Hospital, 7 Chung-Shan South Road,
(T.T.F. Shih).
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110 M.-S. Tsai et al.Conclusion: Reduced BMD was prevalent among HIV-infected Taiwanese adults on cART.
Increased age, lower BMI, and exposure to antiretroviral therapy were significantly associated
with decrease of BMD.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.a cross-sectional survey of BMD at the National TaiwanIntroduction
Widespread use of combination antiretroviral therapy
(cART) has led to dramatic decline in human immunodefi-
ciency virus (HIV)-related morbidity and mortality.1 Pro-
longed antiretroviral therapy exposure has been associated
with comorbidities including metabolic syndrome, cardio-
vascular disease, and osteoporosis.2,3 A meta-analytical
review revealed 67% of HIV-infected patients had reduced
bone mineral density (BMD).4 Compared with HIV-
uninfected controls, HIV-infected patients had a 6.4-fold
increased odds of reduced BMD and a 3.7-fold increased
odds of osteoporosis.4 A large cohort study revealed that
among 671 HIV-infected patients with a median follow-up
of 2.5 years, 12.5% progressed to osteopenia and 15.6% to
osteoporosis.5
For an individual, osteopenia carries a 2-fold increase in
risk for fracture compared with normal BMD, and a history
of osteoporosis without fracture carries a 4- to 5-fold;
individuals with osteoporosis with a history of fracture
increases the risk for recurrent fractures by 20-fold.6,7 In
a population-based U.S. study, HIV-infected individuals had
a higher fracture rate than non-HIV-infected patients (2.87
vs. 1.77 fractures per 100 persons).8
The mechanisms underlying changes in bone metabolism
among HIV-infected patients are unclear but likely multi-
factorial. Traditional risk factors includes female sex, low
body mass index (BMI), physical inactivity, steroid use,
advanced age, decreased intake of calcium and vitamin D,
duration of menopause, smoking, and low testosterone lev-
els.9e12 Although racial differences in BMD have been re-
ported,13 epidemiologic studies of BMD among HIV-infected
patients are rarely conducted among Asian populations.14
Tenofovir, a nucleotide analog HIV reverse transcriptase
inhibitor, was approved by the U.S. Food and Drug Adminis-
tration on October 26, 2001. Metabolic bone abnormalities
have been seen in young animals given high-dose tenofovir
and HIV-infected adults treated with tenofovir.15,16 In
Taiwan, tenofovir was approved for use in adults with HIV
infection after August 2007. Theobjectives of this studywere
to determine the prevalence of and associated factors with
reduced BMD in a cohort of HIV-infected adult patients
before introduction of tenofovir in Taiwan.
Methods
The study was approved by the Research Ethics Committee
of the hospital and all participants gave written informed
consent.
Study setting and population
From March 2002 to April 2006, HIV-infected patients aged
20 years who sought HIV care were invited to participate inUniversity Hospital. Patients were excluded if they had
received growth hormone, testosterone, bisphosphonates,
immunosuppressants, chemotherapy, or steroids; were
pregnant; or had a history of hospitalization or immobiliza-
tion within the previous three months.
Epidemiologic investigation
After enrolment, a standardized case report form was used
to collect information on demographics (age and sex),
menopause, smoking habit, BMI, comorbid conditions
(including kidney disease or chronic viral hepatitis), current
and previous antiretroviral regimens, and cumulative
duration of antiretroviral therapy from medical record
review.
Laboratory and radiographic investigations
Routine laboratory testing (including hematologic,
biochemical, immunologic, and virologic investigations)
were performed every 3e6 months following the national
guidelines for treatment and management of HIV-infected
adults in Taiwan.17 The laboratory results were entered into
a large computer database. Plasma HIV RNA load was
quantified using the CobasAmplicor HIV-1 Monitor test
(CobasAmplicor version 1.5, Roche Diagnostics Corporation,
IN, USA) with a lower detection limit of 50 copies/mL (1.7
log10 copies/mL), and CD4 lymphocyte count was deter-
mined using FACFlow (BD FACS Calibur, Becton Dickinson,
CA, USA). The CD4 count and plasma HIV RNA load were
monitored 1 month after initiation of cART in antiretroviral-
naive patients, or change of regimens in the face of viro-
logical failure; and every 3e6 months thereafter according
to the national HIV treatment guidelines.
BMD was measured with the use of dual-energy X-ray
absorptiometry (DXA) scan. The BMD and T score (expressed
as standard deviation units in comparison with young
normal reference value) of the lumbar spine were
measured using the same DXA device (Lunar Prodigy; GE
Healthcare, Diegem, Belgium).
Definitions
CART was defined as a combination of at least 3 anti-
retroviral agents that contained 2 nucleoside reverse-
transcriptase inhibitors (NRTIs) plus 1 or 2 protease inhibi-
tors or 1 non-nucleoside reverse-transcriptase inhibitor
(NNRTI) or triple NRTIs.
Based on the World Health Organization (WHO)
criteria,18 osteopenia was defined as a BMD T-score
between 1.0 and 2.5, and osteoporosis was defined as
a BMD T-score less than or equal to 2.5.
Reduced BMD and HIV infection 111Being underweight was defined as having a BMI< 18.5
kg/m2 based on the WHO standards for Asian populations.19
Duration on antiretroviral therapy was calculated by the
number of days or weeks of an antiretroviral agent used.
Length of time after HIV diagnosis was defined as the
interval between the date of the first documented HIV-
positive test result and the date of enrollment into this
study.
The prevalence and associated factors of reduced BMD
was determined based on the first DXA scan available.
Variables from the DXA scan were treated as ordinal
(normal values, osteopenia, or osteoporosis).
Statistical analyses
Parametric data were contrasted using an analysis of vari-
ance (ANOVA). Nonparametric data, expressed as median
and interquartile range (IQR), were compared using the
Kruskal-Wallis test. Categorical variables were compared
using the chi-square test or the Fisher exact test. Multi-
variate linear regression and ordinal logistic regression
models were applied to correlate the effect of the inde-
pendent variables (clinical and demographic characteris-
tics) with the results of DXA scan. The regression models
were built using a stepwise procedure. The p value for
inclusion of a covariate in the model was set at 0.15, and
the p value for removal of the covariate was set at 0.20.
The confidence interval (CI) was set at 95%. All statisticalTable 1 Baseline characteristics of the HIV-infected patients wi
All
(nZ 320)
Normal
(nZ 19
Male, n (%) 290 (90.6) 173 (8
Menopause, n (%) 14 (46.7) 7 (3
Median age, (IQR) y 37.3 (31.4e44.5) 37.1 (3
>65 y, n (%) 6 (1.9) 4 (2
MSM, n (%) 201 (62.8) 127 (6
Median length of time after
HIV diagnosis (IQR), y
1.3 (0.4e3.3) 1.1 (0
Median BMI (IQR), kg/m2 21.4 (19.8e23.0) 21.8 (2
BMI< 18.5 kg/m2, n (%) 31 (9.7) 11 (5
BMI, 18.5 to 23 kg/m2, n (%) 203 (63.4) 121 (6
Smoking, n (%) 133 (41.5) 83 (4
Hepatitis B or C co-infection, n (%) 80 (25.0) 50 (2
Median CD4þ count (IQR) (cells) 286 (169e455) 302 (1
Plasma HIV RNA load< 400
copies/ml, n (%)
229 (72) 140 (7
On cART, n (%) 302 (94.4) 179 (9
Median duration on cART (IQR), mo 15.6 (3.6e42.1) 13.2 (2
Cumulative antiretroviral
exposure (IQR), mo
NRTI 14.3 (2.9e39.2) 11.2 (2
NNRTI 6.2 (0e18.6) 5.7 (0
PI 0.8 (0e21.4) 0.3 (0
a See definitions in Methods section.
b Comparison of the three groups.
BMIZ body mass index; cARTZ combination antiretroviral therapy;
MSM Z men who have sex with men; NNRTIZ non-nucleoside revers
transcriptase inhibitor; PIZ protease inhibitor.tests were two-tailed, and p values< 0.05 were considered
to be statistically significant. The analysis was conducted
using the statistical package SAS 9.2 (SAS Institute Inc.,
Cary, NC, USA).Results
Patient characteristics
During the 4-year study period, 320 patients participated in
the survey. The characteristics of the patients are shown in
Table 1. There were 290 males (90.6%) and 30 females
(9.4%). The median age was 36.5 years (IQR, 30.6e41.6) for
males and 47.0 years (IQR, 35.6e53.7) for females
(p< 0.01). The mode of HIV transmission among males was
predominantly homosexual contact (69.3%), followed by
heterosexual contact (30.3%), whereas all of the females
acquired HIV through heterosexual contact.
At the time of the survey, 302 (94.4%) of the patients
were receiving cART. The median cumulative duration on
treatment was 14.3 months (IQR, 2.9e39.2) for NRTIs, 6.2
months (IQR, 0.0e18.6) for NNRTIs and 0.8 months (IQR,
0.0e21.4) for protease inhibitors.
Data on BMI were available for 317 patients (287 males
and 30 females). The median BMI was 21.4 kg/m2 (IQR,
19.8e23.0). BMI was < 18.5 kg/m2 in 31 of these patients
(9.7%). There was no statistically significant differenceth normal bone mineral density, osteopenia, and osteoporosis
4)
Osteopeniaa
(nZ 114)
Osteoporosisa
(nZ 12)
p valueb
9.1) 108 (94.7) 9 (75.0) <0.01
3.3) 5 (83.3) 2 (66.7%) 0.07
1.3e43.4) 37.0 (30.5e44.5) 49.0 (40.2e56.1) 0.15
.1) 1 (0.9) 1 (8.3) 0.19
5.4) 70 (61.4) 4 (33.3) 0.08
.3e3.2) 1.6 (0.6e3.4) 1.9 (0.5e3.6) 0.46
0.3e23.5) 21.0 (19.6e22.6) 19.2 (17.9e21.9) <0.01
.7) 15 (13.1) 5 (41.7) <0.01
2.3) 76 (66.7) 6 (50.0) 0.45
2.8) 47 (41.2) 3 (25.0) 0.48
5.7) 25 (21.9) 5 (41.7) 0.30
68e478) 277 (174e425) 187 (111e364) 0.10
2.1) 81 (71.1) 8 (66.7) 0.76
2.2) 111 (97.3) 12 (100) 0.12
.4e41.9) 18.0 (6.1e40.8) 27.6 (13.2e44.4) 0.35
.0e40.6) 14.8 (5.6e39.1) 27.2 (13.5e44.2) 0.37
e17.0) 6.5 (0.2e19.1) 14.0 (0.8e20.9) 0.21
e20.9) 2.2 (0e22.5) 7.2 (0.01e34.8) 0.71
HIVZ human immunodeficiency virus; IQRZ interquartile range;
e-transcriptase inhibitor; NRTIZ nucleoside/nucleotide reverse-
Figure 1. Correlations for age, cART duration, BMI, and BMD.
Scatter plot with 70% and 80% prediction ellipses. Pearson
correlation coefficient of BMD with age, cART duration, and
BMI were 0.156, 0.136, and 0.197 respectively. BMDZ bone
mineral density; BMIZ body mass index; cART Z combination
antiretroviral therapy.
112 M.-S. Tsai et al.between males and females in terms of BMI (21.9 vs. 20.8;
pZ 0.12).
Prevalence of low BMD and associated factors
Based on the WHO criteria, osteopenia was diagnosed in
114 patients (35.6%) and osteoporosis in 12 patients (3.8%).
The median BMD was 0.94 g/cm2 (IQR, 0.87e1.04). There
were statistically significant sex differences in the distri-
bution of patients’ diagnostic category (pZ 0.003).
Osteopenia was diagnosed in 37.2% and 20.0% of males and
females, respectively. Osteoporosis was diagnosed in 3.1%
and 10.0% of males and females, respectively. The median
BMD was similar in both groups (0.94 vs. 0.96 g/cm2;
pZ 0.58).
In univariate analysis, there was a statistically significant
association between reduced BMD (osteopenia and osteo-
porosis) and being underweight (p< 0.01). No association
was found between reduced BMD and a specific class of
antiretroviral agents.
Taking the DXA value as a numeric variable, the corre-
lations for age, cART duration, BMI, and BMD were shown in
Fig. 1 with Pearson correlation coefficients 0.156,
0.136, and 0.197, respectively. The following factors were
significantly associated with reduced BMD in multivariate
linear regression: lower BMI, increased age, and longer
duration of antiretroviral therapy (Table 2).
When we analyzed DXA values as a ordinal variable by
classifying the results as normal, osteopenia, or osteopo-
rosis, the only significant factor related to reduced BMD was
being underweight (BMI< 18.5 kg/m2; proportional odds
ratio, 4.12; 95% CI, 1.93e8.82; pZ 0.0003; Table 2), which
was consistent with the result of dichotomous analysis
(normal vs. low BMD, odds ratio, 3.28; 95% CI, 1.48e7.28;
pZ 0.0003).
Discussion
In this cross-sectional survey, we found that reduced BMD
was common among HIV-infected adults in Taiwan. More
than one third of the patients had osteopenia and 3.8% had
osteoporosis. Compared with a nationwide representative
sample of 1121 adult participants in Taiwan, the prevalence
of osteopenia and osteoporosis at lumbar spine in our study
(35.6% and 3.8%) was similar to older population aged
60e69 years (32.1% and 4.8%), respectively.20
The prevalence of reduced BMD ranges from 23% to 89%
in various HIV studies.21e26 Although the prevalence of our
study falls within the range of those of other studies, the
difference of prevalence of reduced BMD among the studies
may be explained by the populations studied and the
method of BMD measurement also contributes to difference
in reported prevalence. Knobel et al27 reported the highest
prevalence (89%) in older participants that included more
female patients (27%). The T-score at the femoral neck
quantitatively evaluates the cortical bone tissue, whereas
the T-score at the lumbar spine quantitatively evaluates
the trabecular bone tissue. In our study, we only measured
BMD of the lumbar spine by DXA, which precluded us from
estimating the cortical bone demineralization. The preva-
lence of reduced bone mineral density was diverse atdifferent sites, and the prevalence ratio of femoral neck to
lumbar spine among different age groups in previous study
was around 1.6e3.6.20 Additionally, we excluded patients
who had received drugs potentially lowering bone mass or
Table 2 Regression models
Multivariate linear regression: factors associated with BMD
BMDZ 0.8460.019Age0.016(duration of cART)þ 0.009BMI
R2Z 0.21, p< 0.001
Variable Coefficient 95% CI p value
Constant 0.846 0.717 0.975 0.001
Age (y) 0.0019 0.033 0.005 0.006
Duration of antiretroviral therapy (mo) 0.016 0.025 0.009 0.007
BMI (kg/m2) 0.009 0.005 0.015 0.002
Ordinal logistic regression: factors associated with osteopenia and osteoporosis vs. normal/osteoporosis vs. osteopenia, and
normal
Variable OR (95% CI) p value, univariate Adjusted OR (95% CI) p value, multivariate
BMI< 18.5 kg/m2 3.80 (1.81e8.01) 0.004 4.12a (1.93e8.82) 0.0003
a Adjusted for age and sex.
BMIZ body mass index; BMDZ bone mineral density; CIZ confidence interval; ORZ odds ratio.
Reduced BMD and HIV infection 113had a history of immobilization/hospitalization within the
previous 3 months. It was reasonable to infer that the
prevalence of reduced BMD was underestimated.
In our study, two traditional factors (older age and lower
BMI) were associated with reduced BMD. In a meta-analysis
of 10 published studies, unadjusted BMD was lower by
4.4e7.0% in the HIV-infected groups than the healthy
controls (p< 0.01), and after adjustment for body weight,
residual between-groups differences in BMD were reduced
47e50%.28 Lower BMI has been singled out as the most
important factor associated with reduced BMD in HIV-
infected patients.
Chronic inflammation caused by HIV infection has been
associated with increased bone resorption in chronically
infected patients with high plasma HIV RNA load.29 A direct
effect of HIV upon osteogenic cells, the persistent activa-
tion of proinflammatory cytokines, and alterations in the
metabolism of vitamin D are observed in HIV-infected
patients not receiving cART.30,31 In our participants, the
median length of time after HIV diagnosis was 1.3 years,
which was shorter compared with the median duration of
cART for the participants in a meta-analytic review (4.1e10
years),4 and more than 70% of our patients had achieved
virologic suppression, which may facilitate restoration of
the bone-remodeling process.29
In this cross-sectional study, we also identified the
association between reduced BMD and time on cART. In
a number of randomized controlled trials, accelerated bone
loss has been demonstrated in the initial 6e12 months after
initiation of cART followed by stabilization of BMD there-
after.32,33 Longitudinal follow-up studies are warranted to
assess the long-term effect of cART and ageing on the
evolution of BMD among HIV-infected patients.
Because cART comprises of a combination of 2 or more
antiretroviral agents of the three classes of antiretroviral
therapy, attribution of reduced BMD to a specific class of
antiretroviral agent is not possible. Previous studies have
associated protease inhibitors with loss of BMD,21,34
although the effect varies with the protease inhibitor
analyzed.33,35 In addition, efavirenz has recently been
associated with a significant decrease in vitamin D levels
that could lead to accelerated bone loss.36 Although other
NRTIs such as stavudine and zidovudine have been demon-
strated to be more likely than tenofovir to causemitochondrial toxicity,37 tenofovir is the most widely cited
antiretroviral agent that is involved in bone demineraliza-
tion.16,33,38 Our study was conducted before introduction of
tenofovir into Taiwan, and therefore we were not able to
evaluate the association between specific class of anti-
retroviral agent and reduced BMD. However, with
increasing use of tenofovir in Taiwan, long-term effects of
tenofovir on BMD in Taiwanese population requires moni-
toring and further studies.
There are several limitations to our study. Being a cross-
sectional study precluded us from establishing causal rela-
tionships between factors identified and reduced BMD.
Second, the sample size was relatively small, and the
majority of our patients were middle-aged males. The
results may not be generalizable to all HIV-infected
patients in Taiwan. Third, we did not have any informa-
tion on bone remodeling biochemical markers and gonadal
status of our patients; indeed, hypogonadism may compli-
cate HIV infection and it is the main cause of male osteo-
porosis. Lastly, like the majority of HIV-infected persons
who receive long-term antiretroviral therapy, many
patients in our study switched antiretroviral regimens
(67.2% had switched cART, and 40.4% had switched cART
more than once (data, not shown)) during the follow-up
because of virologic failure and/or intolerable side effects.
The evaluation of the impact of specific classes of anti-
retroviral medications on reduced BMD was disallowed.
In conclusion, the prevalence of reduced BMD is high in
HIV-infected patients in Taiwan, and is associated with
increased age and time on antiretroviral treatment and
being underweight. We suggest that HIV infection should be
considered as a risk factor for bone disease. HIV-infected
post-menopausal women and HIV-infected men 50 years
should receive BMD screening especially those with addi-
tional risk factors for bone loss such as low BMI and expo-
sure to cART. Smoking cessation, limitation of alcohol
intake, adequate nutrition, particularly calcium
(1000e1500 mg daily), and vitamin D intake (800e1000 IU
of vitamin D daily) were recommended.39Conflicts of interest
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